A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Public ClinicalTrials.gov record NCT07647328. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
SERAFA-1: A Single Arm, Open Label, Multicentre, Phase IIIb Study Of Camizestrant Plus Ribociclib in 1st Line Treatment of ER Positive, HER2-negative Advanced Breast Cancer Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to investigate the efficacy, safety, and tolerability of camizestrant in combination with ribociclib in patients with ER+ HER2- BC who have not received any other systemic treatment for advanced disease. Participants will be treated within the trial until they discontinue the study treatment for any reason.
Study identification
- NCT ID
- NCT07647328
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 150 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 14, 2026
- Primary completion
- Feb 27, 2029
- Completion
- Feb 27, 2029
- Last update posted
- Sep 7, 2026
2026 – 2029
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Duarte | California | 91010 | Not yet recruiting |
| Research Site | Palo Alto | California | 94304 | Not yet recruiting |
| Research Site | Marietta | Georgia | 30060 | Recruiting |
| Research Site | Evanston | Illinois | 60201 | Not yet recruiting |
| Research Site | Edgewood | Kentucky | 41017 | Not yet recruiting |
| Research Site | Louisville | Kentucky | 40202 | Not yet recruiting |
| Research Site | Reno | Nevada | 89502 | Not yet recruiting |
| Research Site | Sioux Falls | South Dakota | 57105 | Not yet recruiting |
| Research Site | Nashville | Tennessee | 37204 | Not yet recruiting |
| Research Site | Fort Worth | Texas | 76104 | Not yet recruiting |
| Research Site | Kingwood | Texas | 77339 | Recruiting |
| Research Site | Midlothian | Virginia | 23114 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 77 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07647328, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 7, 2026 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07647328 live on ClinicalTrials.gov.